Immuneering Fast Track for IMM-1-104 in First-line Pancreatic Cancer

 IMM-1-104 Fast Track designation now granted for the treatment of both first and second-line pancreatic ductal adenocarcinoma (PDAC); provides potential to accelerate IMM-1-104’s path to U.S. FDA submission for PDAC -

- Phase 2a trial of IMM-1-104 includes multiple arms open to first-line pancreatic cancer patients, as well as arms open to patients with second-line pancreatic cancer, RAS-mutant melanoma, and RAS-mutant lung cancer -

- Company expects initial data from multiple arms of its Phase 2a clinical trial in the second half of 2024 -

https://www.globenewswire.com/news-release/2024/07/31/2922221/0/en/Immuneering-Granted-FDA-Fast-Track-Designation-for-IMM-1-104-in-First-line-Pancreatic-Cancer.html